Skip to main content


Fig. 2 | BMC Musculoskeletal Disorders

Fig. 2

From: Vertebral bone marrow fat fraction changes in postmenopausal women with breast cancer receiving combined aromatase inhibitor and bisphosphonate therapy

Fig. 2

PDFF maps [%] of a patient from the AI+BP group (upper row) and the AI-BP group (bottom row), respectively, at baseline (left column) and follow-up (right column). Mean PDFF values averaged over L1 to L5 at baseline and follow-up were equal to 50.16 and 55.80%, respectively, for the AI+BP patient (upper row); and equal to 30.78 and 34.14%, respectively, for the AI-BP patient (lower row)

Back to article page